Trade Gilead ^GILD

Promising Medical Stocks Worth Watching - May 9th - Stock Observer

Money Concepts Capital Corp Sells 4,126 Shares of Gilead Sciences, Inc. $GILD - Daily Political

Bailard Inc. Has $90.10 Million Stock Position in Gilead Sciences, Inc. $GILD - Daily Political

Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs

LA500 2026: Arie Belldegrun

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

Kepler Cheuvreux Suisse SA Acquires New Position in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Acquired by ABN AMRO Bank N.V.

Swiss Life Asset Management Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD - Daily Political

Royal Bank Of Canada Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $122.00 - Stock Observer

Did Gilead's Mixed Q1, Buybacks and HIV Milestone Just Shift Gilead Sciences' (GILD) Investment Narrative? - Simply Wall St News

Gilead Sciences (GILD) Receives a Buy from Citi

NewEdge Wealth LLC Grows Holdings in Gilead Sciences, Inc. $GILD - Stock Observer

Promising Pharmaceutical Stocks To Watch Now - May 9th - Stock Observer

Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $146.00 at Leerink Partners - Zolmax

Leerink Partners Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $146.00 - Stock Observer

Crossmark Global Holdings Inc. Buys 23,719 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences (NASDAQ:GILD) Price Target Cut to $146.00 by Analysts at Leerink Partners - Daily Political

Morgan Stanley Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - Daily Political

Gilead Sciences (NASDAQ:GILD) Stock Rating Lowered by Wall Street Zen

Gilead Sciences (GILD) Margin Surge Tests Cautious Growth Narratives After FY 2025 Results

RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)

Prothena (PRTA) Gets a Hold from RBC Capital

Gilead Earnings: Strong HIV Growth Counters CAR-T Weakness, but Anito-Cel Launch in Focus | Morningstar

GILD Maintained by RBC Capital -- Price Target Lowered to $122

Gilead Sciences (NASDAQ:GILD) Price Target Cut to $122.00 by Analysts at Royal Bank Of Canada

Gilead Sciences, Inc. (NASDAQ:GILD) Plans Quarterly Dividend of $0.82

Virtus Family Office LLC Buys New Shares in Gilead Sciences, Inc. $GILD

Gilead Sciences Raises 2026 Sales Forecast Amid Acquisition Costs, ETPharma

Gilead Sciences (GILD) Announces Quarterly Dividend and Adjusts 2026 Outlook

Gilead Sciences, Inc. $GILD Shares Sold by Patton Albertson Miller Group LLC - Zolmax

Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Quarterly Dividend of $0.82 - Stock Observer

Gilead Sciences (GILD) Stock Drops Despite Q1 Beat on Massive Acquisition Charges

Gilead Sciences, Inc. $GILD Holdings Decreased by GRIMES & Co WEALTH MANAGEMENT LLC

Gilead Sciences (GILD) Reports Strong Q1 2026 Earnings and Raises Sales Guidance

Gilead Sciences, Inc. $GILD Shares Sold by Patton Albertson Miller Group LLC - Daily Political

Gilead Sciences Q1 Earnings Call Highlights

Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results

Diagnosing and defining MASLD in people living with chronic hepatitis B

Gilead Sciences Inc. Reports Advance In Q1 Income

Gilead Sciences (NASDAQ:GILD) Issues FY 2026 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) Releases FY 2026 Earnings Guidance - Daily Political

Gilead Sciences shares decline 1.36% ahead of first quarter earnings

A Look At Gilead Sciences (GILD) Valuation After FDA Priority Review For New HIV Tablet

WealthShield Partners LLC Makes New $1.73 Million Investment in Gilead Sciences, Inc. $GILD - Stock Observer

Indivisible Partners Purchases New Stake in Gilead Sciences, Inc. $GILD

Gilead Sciences News | Markets Insider

Galapagos rapporteert financiële resultaten over het eerste kwartaal van 2026 en geeft bedrijfsupdate

Gilead Case Could Reshape Drug Liability: California Brief

Swedbank AB Grows Stock Position in Gilead Sciences, Inc. $GILD - Zolmax

Gilead Sciences, Inc. $GILD Shares Sold by Sprucegrove Investment Management Ltd.

Equitable Trust Co. Has $6.07 Million Holdings in Gilead Sciences, Inc. $GILD

Mitsubishi UFJ Asset Management Co. Ltd. Has $330.64 Million Position in Gilead Sciences, Inc. $GILD - Stock Observer

GILEAD SCIENCES, INC. Reduces Stake in Arcellx Inc by 6,720,703 Shares

RNC Capital Management LLC Increases Stake in Gilead Sciences, Inc. $GILD

Morse Asset Management Inc Invests $1.22 Million in Gilead Sciences, Inc. $GILD

Use of Gilead's HIV prevention shot rises, but US insurance gaps remain - Yahoo News Canada

Gilead Sciences, Inc. $GILD Shares Acquired by M&T Bank Corp

Gilead Sciences, Inc. $GILD Shares Purchased by QRG Capital Management Inc. - Stock Observer

Alliance Wealth Advisors LLC UT Cuts Stake in Gilead Sciences, Inc. $GILD

Earnings Strength Moves Into Focus as the Busiest Week of Q1 Season Begins | Investing.com UK

Earnings Strength Moves Into Focus as the Busiest Week of Q1 Season Begins | Investing.com Canada

Gilead Sciences, Inc. $GILD Shares Bought by Triasima Portfolio Management inc.

Can You Sue A Drug Company For Not Inventing Faster?

Gilead Sciences, Inc. $GILD Shares Sold by Varma Mutual Pension Insurance Co - Stock Observer

Pinnacle Wealth Management Advisory Group LLC Cuts Stock Position in Gilead Sciences, Inc. $GILD - Stock Observer

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Hussman Strategic Advisors Inc. Cuts Stake in Gilead Sciences, Inc. $GILD - Daily Political

Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sigma Planning Corp

Assessing Gilead Sciences (GILD) Valuation As Long Term Returns Contrast With Recent Share Performance

GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions

Biopharma M&A Surge Expected in 2026 Amid Patent Expirations

Big Pharma M&A set for mega year as patent expiries drive deal urgency

Jennison Associates LLC Buys 741,044 Shares of Gilead Sciences, Inc. $GILD - Zolmax

Oppenheimer & Co. Inc. Cuts Position in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System

US Bancorp DE Has $105.44 Million Stock Position in Gilead Sciences, Inc. $GILD

Fifth Third Bancorp Increases Position in Gilead Sciences, Inc. $GILD

Danske Bank A S Sells 45,529 Shares of Gilead Sciences, Inc. $GILD

Keybank National Association OH Has $14.15 Million Stock Position in Gilead Sciences, Inc. $GILD - Zolmax

Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 10,000 Shares - Zolmax

Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now?

Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted - Stock Observer

Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc.

Gilead Sciences, Inc. $GILD Position Trimmed by State of New Jersey Common Pension Fund D

FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst

Is It Time To Revisit Gilead Sciences (GILD) After Recent Share Price Pullback

Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock

GILD: Gilead's New HIV Treatment Gains FDA Acceptance

How Investors May Respond To Kymera Therapeutics (KYMR) FDA Fast Track Win And Gilead Trial Expansion

Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock